Business Information
The group's principal activities are to discover and develop pharmaceutical products for the treatment of serious medical conditions. The product pipeline includes product candidates for the treatment of obesity, rheumatoid arthritis and other inflammatory conditions, cancer and related disorders, allergies, asthma, and other diseases and disorders. The group has formed collaborations to advance other research and development efforts. It is conducting research with the procter & gamble company in muscle diseases and also collaborating with medarex, inc. To discover, develop, and commercialize certain human antibodies as therapeutics. In partnership with amgen inc., the group has development rights to neurotrophin-3, or nt-3, a clinical compound for the treatment of constipating conditions, although there are no ongoing development activities for nt-3 at this time.
|
|
Name |
Title
|
Email
|
| Roy Vagelos | Chmn. | Available | | George Yancopoulos | Dir., Exec. VP, Pres. - Regeneron Research Laboratories, Chief Scientific Officer | Available | | Murray Goldberg | Exec. VP - Finance, Administration, CFO, Treasurer, Assist. Sec. | Available | | Neil Stahl | Sr. VP - Preclinical Development, Biomoleculer Science | Available | | Peter Powchik | Sr. VP - Clinical Development | Available
|
|
|
Year |
Sales |
Net Income |
| 2006 | 63,447 | (102,337) | | 2005 | 66,193 | (95,446) | | 2004 | 174,017 | 41,699
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
